OMER, Israel, July 15, 2014 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and procedures, and maker of the innovative MUSE(TM) System, an incisionless surgical procedure for severe GERD patients, today announced key appointments to its global commercial team.
"The addition of these senior executives to our commercial team will help drive the transformation of Medigus into a global leader in the minimally invasive endosurgical market, offering surgeons and therapeutic endoscopists an innovative and minimally invasive solution for patients with severe or refractory GERD," said Chris Rowland, CEO, Medigus Ltd.
Key appointments include:
•Tom Dempsey, new VP/GM United States, brings a diverse functional experience, including 19 years leading start-ups through established medical device companies including Boston Scientific and Endogastric Solutions (EGS), where he was VP, Commercialization. Mr. Dempsey was previously CEO of Medical Diagnostic Technologies and Peak Heart.
•Sheila Stevens, PhD, Sr. Director Regulatory and Clinical, has an extensive track record within Clinical and Regulatory Affairs including positions at Clear Catheter Systems, BaroSense, Inc., Apneon, and Kyphon.
•Lori Saper, Sr. Director Professional Education, has vast experience working as an educator in the Operating Room (OR) and ICU environment with surgical and clinical teams. Ms. Saper brings over 20 years of experience in Medical and Clinical Trial Management in Europe and the U.S including positions at BioVentryx, Pioneer Surgical Technology, and Kyphon.
•Milena Ridl, new VP Europe, brings strong commercial and market development experience throughout Europe, including leadership roles at Kyphon, MiMedx and SpineAlign.
"These executives bring significant clinical and marketing expertise commercializing medical devices which will be instrumental as we expand the launch of our flagship MUSE(TM) system worldwide," added Mr. Rowland.
These new team members join Medigus' established operating and R&D team based in Omer, Israel.
Medigus also announced that it has established a subsidiary office in the San Francisco, California Bay Area to drive regional adoption for MUSE(TM) in the U.S.
About the MUSE(TM) System
MUSE(TM), an intuitive endoscopic platform that consists of a single use surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder, performs a true surgical anterior fundoplication in a less invasive way, compared to other methods. This approach uses standard surgical staples with clinical data comparable to current surgical procedures. Furthermore, the system is a single-operator, out-patient procedure and offers patients the potential to eliminate lifelong medication, in addition to less hospital readmissions and hospitalizations, and reduced costs to the healthcare system.
Medigus is leading the transition from invasive gastric surgery procedures to less invasive, patient-friendly techniques through the development of minimally invasive endoscopic devices and procedures. The company's revolutionary MUSE(TM) system enables endoscopists to treat gastroesophageal reflux disease (GERD), a chronic disease with increasing global prevalence, by performing a fundoplication procedure through the mouth. Unlike current fundoplication procedures, the MUSE(TM) system does not require abdominal incisions, which may result in shorter post-procedure recovery. The MUSE(TM) endoscopy system has received FDA clearance and CE mark. Medigus is traded on the TASE (Tel Aviv Stock Exchange). To learn more about the company's minimally invasive technology platform, please visit http://www.medigus.com/.
Chantal Beaudry/Carrie Yamond
Lazar Partners Ltd.
Hayden/ MS-IR LLC
Source: Medigus Ltd.